Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 24 Apr 2003 |
| Genmab, changes management/auditors | 15 Apr 2003 |
| Genmab, quarterly statement of shareholdings 15. April 2003 | 15 Apr 2003 |
| Genmab, notice convening annual general meeting 24 April 2003 | 8 Apr 2003 |
| Genmab, current statement of shareholdings on 21 March 2003 | 21 Mar 2003 |